~~<i id='D6EE5A7CAE'><strike id='D6EE5A7CAE'><tt id='D6EE5A7CAE'><pre id='D6EE5A7CAE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：focus 2025-09-29 21:26:03 - browse：74

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： A new initiative will help leaders fight the next pandemic

hotspot

focus

leisure time

explore

focus

GarryTan,CEOofYCombinatorSebDaly/WebSummiWASHINGTON—InSanFrancisco,YCombinator’sfirebrandchiefexecut

WSS

Average age of first period drops to 11.9 years, study shows

Focused ultrasound for uterine fibroids: an uphill battle

The most pressing bird flu mysteries scientists want answered

Illumina board agrees to spin off Grail, as divestment plans proceed

Sutter Health’s antitrust win overturned by appeals court

Senators tussle over abortion against the backdrop of a presidential campaign

leisure time

knowledge

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sutter Health’s antitrust win overturned by appeals court

What does generative AI mean for health care? We asked experts

Childbirth

In age of alternative facts, a scholarly course on calling out crap

STAT wants to know your pick for a great summer read or listen

In Memoriam: Notable people who died in 2023

iTeos Therapeutics debuts first data on TIGIT

Duchenne breakthrough therapy leaves behind pioneering families

UnitedHealth CEO's Medicaid comments send insurer stocks diving

focus

Startling documents reveal new facets of Sacklers' opioid empire

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Childbirth

Stigma and the return of syphilis

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

focus

leisure time

explore

focus